Roche On The Wrong Side For Once In Shifting Analyst Forecasts
EP Vantage - Seeking Alpha - Sat Jun 06, 7:32AM CDT
Roche 's ( OTCPK:RHHBF ) ( OTCQX:RHHBY ) reputation as a peerless R&D powerhouse has taken a battering in the past year, and as a consequence, two of its abandoned projects have made the list of top downgrades of the past 12 months. On the...
SGYP: 7.24 (+0.12), VRTX: 134.06 (+2.06), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), IBB: 354.74 (+4.02), PBYI: 103.28 (+6.59), NVS: 96.55 (+0.28)
The Battle Of The Bulge
The Nattering Naybob - at Seeking Alpha - Mon May 18, 8:59AM CDT
ABT: 43.41 (+0.29), PFE: 32.97 (+0.35), SYY: 39.95 (+0.58), LO: 71.40 (-0.33), LLY: 81.80 (+0.96), MDRX: 13.27 (+0.03), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), MO: 52.59 (-0.68), ATHN: 136.05 (+0.29), PM: 79.47 (+0.60), JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), AAC: 22.50 (-0.53), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), WTW: 5.91 (-0.09), NVS: 96.55 (+0.28)
The Weekender
Aviate - at Seeking Alpha - Sun May 17, 7:39AM CDT
Rising rates, banks, beta and the pain trade We note a strategy piece by a well-respected strategist this week (JPMorgan) used the word ' reflation ' - one all but removed from investment parlance - with respect to the bond market's rather vicious...
WMT: 64.65 (+0.53), RBS: 10.19 (+0.02), SPY: 196.74 (+0.89), LYG: 4.74 (-0.02), AV: 14.54 (-0.11), MR: 23.46 (-0.14), PSO: 17.67 (-0.07), LBTYK: 43.93 (-0.58), TI: 12.33 (-0.30), LBTYA: 47.33 (-0.44), BHP: 34.07 (+0.13), TEF: 13.08 (-0.22), DIA: 164.39 (+1.00), ING: 15.08 (-0.12), RIO: 37.21 (+0.83), PHG: 25.86 (+0.08), VOD: 34.69 (-0.52), QQQ: 105.57 (+0.58)
Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 533.30 (+2.08), NVS: 96.55 (+0.28)
TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 32.15 (+0.40), NVS: 96.55 (+0.28)
Flexus Shows Other Immuno-Oncology Wannabes How It's Done
EP Vantage - Seeking Alpha - Wed Feb 25, 1:28PM CST
Deal making in the immuno-oncology space was always going to be a big theme of 2015, and Bristol-Myers Squibb ’s (NYSE: BMY ) moves yesterday – most notably the $800m it paid to secure Flexus Biosciences ’ preclinical...
MRK: 52.09 (-0.63), INCY: 131.01 (+6.51), NLNK: 51.03 (+1.84), BMY: 59.22 (+0.47)
Why Don't You Diversify Your Portfolio With Some European Blue Chips?
Gold Finder - at Seeking Alpha - Fri Jan 23, 9:50AM CST
UN: 39.24 (-0.09), HSBC: 39.12 (+0.06), GOOG: 625.77 (+4.42), T: 32.72 (-0.03), BRK.A: 198,329.00 (+690.00), NVS: 96.55 (+0.28)
Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 23.73 (+0.19), AKER: 2.96 (+0.16), WX: 42.90 (-0.10)